IDO2 and neoplasm: Further, excess potassium flux from necrotic tumour cells [149], buildup of extracellular adenosine [150] and tumour release of kynurenine as a metabolic byproduct of tryptophan metabolism by indoleamine 2.3-dioxygenase (IDO) [151] all impair T cell stimulation, effector function and survival.